Necitumumab - NCI - National Cancer Institute
WebNecitumumab is approved to be used with gemcitabine hydrochloride and cisplatin to treat: Squamous non-small cell lung cancer that has metastasized (spread to other parts of the body). It is used as first-line treatment. Necitumumab is also being studied in the treatment of other types of cancer.
Necitumumab: Uses, Interactions, Mechanism of Action
WebNov 30, 2015 · Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, …
Necitumumab - Wikipedia
WebNecitumumab is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR). [3] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non …
Necitumumab: First Global Approval - PubMed
WebNecitumumab is approved as a part of combination therapy (with gemcitabine and cisplatin) in the USA for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC), and regulatory submissions have been made in the EU for this same indication.
Necitumumab Uses, Side Effects & Warnings - Drugs.com
WebDec 26, 2023 · What is necitumumab? Necitumumab is a monoclonal antibody that blocks a certain protein in the body that can affect tumor cell growth. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Necitumumab is used to treat a certain type of non …
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA …
WebNecitumumab is an IgG1 monoclonal antibody and an EGFR antagonist that acts by binding to EGFR and blocking the binding of EGFR to its ligands, ultimately preventing the activation and the dimerization of the receptor. 12 This process may inhibit the EGFR-dependent downstream pathways, thereby blocking EGFR-dependent tumor-cell …
Portrazza (necitumumab) dosing, indications, interactions, …
WebDrugs & Diseases. necitumumab (Rx) Brand and Other Names: Portrazza. Classes: Antineoplastics, EGFR Inhibitors. Print. Dosing & Uses. AdultPediatric. Dosage Forms & Strengths. IV solution....
Necitumumab | Memorial Sloan Kettering Cancer Center
WebDec 12, 2022 · Necitumumab. Adult Medication. This information from Lexicomp ® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand …
Spotlight on necitumumab in the treatment of non-small-cell lung ...
WebFeb 13, 2017 · Abstract. The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted therapy. Epidermal growth factor receptor (EGFR), when aberrantly activated, promotes cell growth and contributes in various ways to the malignant process.
Necitumumab for the treatment of advanced non-small-cell lung ... - PubMed
WebIn the Phase III SQUIRE trial, necitumumab used as first-line therapy in combination with cisplatin and gemcitabine showed a reduction in risk-of-death and a better disease control rate in advanced squamous NSCLC. Thus, necitumumab is now a new first-line treatment option in squamous NSCLC.
Skip to content